Alkermes is a pharmaceutical company specializing in the development of medicines for complex psychiatric and neurological disorders. With a portfolio of proprietary products and a pipeline of clinical candidates, Alkermes leverages its deep neuroscience expertise to address conditions often overlooked or stigmatized. The company's patient-inspired approach, integrated research strategy, and commitment to holistic support for patients and communities distinguish it in the industry.
Alkermes is seeking a Director of Health Economics and Outcomes Research to lead research on alixorexton (formerly ALKS 2680) in Phase 3 and potential registration. The role involves collaborating with various stakeholders to deliver evidence generation plans, identifying research gaps, and developing strategies for effective access and reimbursement. The position operates in a hybrid work model.
Alkermes is a pharmaceutical company specializing in the development of medicines for complex psychiatric and neurological disorders. With a portfolio of proprietary products and a pipeline of clinical candidates, Alkermes leverages its deep neuroscience expertise to address conditions often overlooked or stigmatized. The company's patient-inspired approach, integrated research strategy, and commitment to holistic support for patients and communities distinguish it in the industry.
Dyne Therapeutics